Effect of aspirin on prostanoids and nitric oxide production in streptozotocin-diabetic rats with ischemic retinopathy

被引:25
作者
De La Cruz, JP
Guerrero, A
Paniego, MJ
Arranz, I
Moreno, A
de la Cuesta, FS
机构
[1] Univ Malaga, Sch Med, Dept Pharmacol & Therapeut, Malaga 29071, Spain
[2] Univ Malaga, Sch Med, Dept Ophthalmol, Malaga 29071, Spain
关键词
acetylsalicylic acid; diabetic retinopathy; nitric oxide; prostacyclin;
D O I
10.1007/s00210-001-0507-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The importance in experimental diabetic retinopathy of prostacyclin and nitric oxide (NO), as well as the possible effect of acetylsalicylic acid (ASA), are well known. To investigate the effect of two doses of aspirin in the prevention of retinal ischemia in streptozotocin-diabetic rats, we compared nondiabetic rats and diabetic rats after 1, 2 and 3 months of diabetes, and diabetic rats treated with 2 mg or 10 mg ASA/kg per day p.o. from the first day of diabetes. The parameters determined after 1, 2 and 3 months of development were platelet aggregation, thromboxane B-2 (TxB(2)) production, 6-keto-prostaglandin F-1alpha (stable metabolite of prostacyclin), NO, plasma nitrites/nitrates, and percentage retinal surface occupied by horseradish peroxidase (HRP)-permeable vessels. In diabetic rats platelet aggregation and thromboxane concentration were increased, and prostacyclin, NO and area occupied by HRP-permeable vessels were decreased. Acetylsalicylic acid reduced platelet aggregation, and lowered thromboxane production by 82%-99%. Prostacyclin production was inhibited by 92%-95% with 10 mg ASA/kg per day, and by 8%-20% with 2 mg ASA/kg per day. In diabetic rats NO production increased after 2 and 3 months of treatment to levels seen in nondiabetic rats. The reduction in HRP-permeable retinal surface decreased from a maximum of 87% in DR to 51% after treatment with 2 mg ASA/kg per day, and to 62% after 10 mg ASA/kg per day. We conclude that ASA (2 mg/kg per day and 10 mg/kg per day) increased NO production in streptozotocin-diabetic rats and reduced the degree of retinal ischemia.
引用
收藏
页码:96 / 101
页数:6
相关论文
共 22 条
[1]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[2]  
[Anonymous], 1991, Ophthalmology, V98, P757
[3]  
Bardell AL, 2001, J PHARMACOL EXP THER, V296, P252
[4]  
BAUDOIN C, 1989, DIABETES, V38, P491
[5]   ELECTRONIC AGGREGOMETER - NOVEL DEVICE FOR ASSESSING PLATELET BEHAVIOR IN BLOOD [J].
CARDINAL, DC ;
FLOWER, RJ .
JOURNAL OF PHARMACOLOGICAL METHODS, 1980, 3 (02) :135-158
[6]  
Chakrabarti S, 2000, DIABETES-METAB RES, V16, P393, DOI 10.1002/1520-7560(0000)9999:9999<::AID-DMRR157>3.0.CO
[7]  
2-G
[8]   Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus [J].
De La Cruz, JP ;
Moreno, A ;
Ruiz-Ruiz, MI ;
De La Cuesta, FS .
THROMBOSIS RESEARCH, 2000, 97 (03) :125-131
[9]   Effect of dipyridamole and aspirin on the platelet-neutrophil interaction via the nitric oxide pathway [J].
De la Cruz, JP ;
Blanco, E ;
de la Cuesta, FS .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 397 (01) :35-41
[10]   Endothelial dysfunction in diabetes [J].
De Vriese, AS ;
Verbeuren, TJ ;
Van de Voorde, J ;
Lameire, NH ;
Vanhoutte, PM .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (05) :963-974